Australia markets open in 3 hours 56 minutes

Allogene Therapeutics, Inc. (ALLO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
3.4600-0.0500 (-1.42%)
At close: 04:00PM EDT
3.4600 0.00 (0.00%)
After hours: 04:02PM EDT
Show:
Income statement
Balance sheet
Annual

Cash flow

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Cash flows from operating activities
Net income
-327,265
-327,265
-340,414
-182,051
-316,381
Depreciation & amortisation
14,199
14,199
14,295
10,454
7,586
Deferred income taxes
-
-
-
0
0
Stock-based compensation
65,951
65,951
83,600
80,818
65,261
Change in working capital
-15,305
-15,305
3,897
-31,949
53,922
Accounts payable
-7,502
-7,502
4,868
-767
615
Other working capital
-239,249
-239,249
-225,710
-206,258
-181,051
Other non-cash items
579
579
2,329
-73,129
3,955
Net cash provided by operating activities
-237,733
-237,733
-220,519
-184,812
-115,093
Cash flows from investing activities
Investments in property, plant and equipment
-1,516
-1,516
-5,191
-21,446
-65,958
Acquisitions, net
0
0
0
-17,710
0
Purchases of investments
-438,629
-438,629
-248,109
-525,583
-1,037,591
Sales/maturities of investments
603,434
603,434
359,459
728,394
598,426
Net cash used for investing activities
163,289
163,289
106,159
163,655
-505,123
Cash flows from financing activities
Common stock issued
91,112
91,112
0
0
621,933
Net cash used provided by (used for) financing activities
95,695
95,695
2,950
11,963
633,591
Net change in cash
21,251
21,251
-111,410
-9,194
13,375
Cash at beginning of period
72,196
72,196
183,606
192,800
179,425
Cash at end of period
93,447
93,447
72,196
183,606
192,800
Free cash flow
Operating cash flow
-237,733
-237,733
-220,519
-184,812
-115,093
Capital expenditure
-1,516
-1,516
-5,191
-21,446
-65,958
Free cash flow
-239,249
-239,249
-225,710
-206,258
-181,051